Zacks Research Issues Positive Outlook for Revvity Earnings

Revvity, Inc. (NYSE:RVTY) – Zacks Research boosted their Q2 2025 earnings per share estimates for shares of Revvity in a report released on Monday, November 25th. Zacks Research analyst R. Department now anticipates that the company will earn $1.28 per share for the quarter, up from their previous estimate of $1.27. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Revvity’s FY2025 earnings at $5.17 EPS, Q2 2026 earnings at $1.40 EPS and FY2026 earnings at $5.67 EPS.

Several other brokerages have also recently issued reports on RVTY. TD Cowen upped their price objective on Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Robert W. Baird upped their price target on Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Sanford C. Bernstein reduced their price objective on Revvity from $150.00 to $145.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Raymond James boosted their target price on shares of Revvity from $144.00 to $146.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Barclays reduced their price target on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a research report on Monday. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $131.73.

Revvity Stock Performance

Shares of RVTY stock opened at $116.23 on Thursday. The stock has a market capitalization of $14.15 billion, a price-to-earnings ratio of 56.15, a PEG ratio of 2.86 and a beta of 1.05. Revvity has a one year low of $86.30 and a one year high of $129.50. The company’s 50-day simple moving average is $120.05 and its 200-day simple moving average is $115.89. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.97 and a current ratio of 3.56.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.15. The firm had revenue of $684.10 million for the quarter, compared to analysts’ expectations of $679.66 million. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.18 earnings per share.

Institutional Trading of Revvity

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Revvity by 1.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 168,547 shares of the company’s stock valued at $17,698,000 after acquiring an additional 2,153 shares in the last quarter. California State Teachers Retirement System lifted its position in Revvity by 0.8% in the first quarter. California State Teachers Retirement System now owns 196,168 shares of the company’s stock worth $20,598,000 after purchasing an additional 1,484 shares during the period. Wahed Invest LLC boosted its stake in Revvity by 13.6% during the 1st quarter. Wahed Invest LLC now owns 2,399 shares of the company’s stock valued at $252,000 after purchasing an additional 288 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Revvity during the 1st quarter valued at $1,214,000. Finally, DekaBank Deutsche Girozentrale raised its stake in shares of Revvity by 27.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 84,383 shares of the company’s stock worth $8,790,000 after buying an additional 18,367 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Tajinder S. Vohra sold 2,154 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the sale, the insider now owns 19,652 shares of the company’s stock, valued at $2,392,237.96. This represents a 9.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.24%. Revvity’s dividend payout ratio is presently 13.53%.

Revvity declared that its Board of Directors has authorized a stock buyback plan on Monday, November 4th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to reacquire up to 6.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.